Bausch & Lomb Corp.
- BLCO · NYSE
- Ophthalmic Goods
- Vaughan, A6
- 13,000 employees
- CIK 0001860742
Updated from SEC filings through
Top things to know
Executives
- Thomas J. Appio Chairman and interim CEO, Bausch + Lomb 8-K, October 28, 2026
- Brent L. Saunders Chairman of the Board and CEO Form 4, August 7, 2026
-
Sam Eldessouky EVP and CFO Form 4, August 7, 2026 -
Andrew J. Stewart President, GPIC Form 4, August 7, 2026 -
Luc Bonnefoy President, Surgical Form 4, August 7, 2026 - A. Robert D. Bailey EVP & Chief Legal Officer Form 4, August 7, 2026
What leadership is saying
“Our third-quarter performance reflects the strength and breadth of the business, with growth across all three segments and continued expansion in profitability”
Earnings press release (8-K Ex. 99.1), filed October 28, 2026
Bausch & Lomb Corp is a U.S. public company in ophthalmic goods (SIC 3851), headquartered in Vaughan, A6. It trades as BLCO on NYSE. Revenue was $5.1B in the fiscal year ending December 31, 2025, +6.5% from the year before. It reported about 13,000 employees.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.1B 10-K, 2026-02-18 | $4.8B 10-K, 2026-02-18 | $4.1B 10-K, 2026-02-18 | $3.8B 10-K, 2025-02-19 | $3.8B 10-K, 2024-02-21 |
| Operating income | $113M 10-K, 2026-02-18 | $162M 10-K, 2026-02-18 | $130M 10-K, 2026-02-18 | $207M 10-K, 2025-02-19 | $329M 10-K, 2024-02-21 |
| SG&A | $2.2B 10-K, 2026-02-18 | $2.1B 10-K, 2026-02-18 | $1.7B 10-K, 2026-02-18 | $1.5B 10-K, 2025-02-19 | $1.4B 10-K, 2024-02-21 |
| Net income | -$360M 10-K, 2026-02-18 | -$317M 10-K, 2026-02-18 | -$260M 10-K, 2026-02-18 | $6.0M 10-K, 2025-02-19 | $182M 10-K, 2024-02-21 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Thomas J. Appio | Chairman and interim CEO, Bausch + Lomb | 8-K, October 28, 2026 |
| Brent L. Saunders | Chairman of the Board and CEO | Form 4, August 7, 2026 |
| Brenton L. Saunders | Board member (per proxy) bio: Chairman of the Board and Chief Executive Officer | DEF 14A, April 10, 2026 |
| | EVP and CFO | Form 4, August 7, 2026 |
| | President, GPIC | Form 4, August 7, 2026 |
| | President, Surgical | Form 4, August 7, 2026 |
| A. Robert D. Bailey | EVP & Chief Legal Officer | Form 4, August 7, 2026 |
| Frederick Munsch Senior Vice President- Controller and Chief Accounting Officer at Bausch + Lomb Corporation | SVP, Controller and CAO | Form 4, August 12, 2026 |
| | EVP of R&D and CMO | Form 4, August 7, 2026 |
What Bausch & Lomb Corp does
Bausch + Lomb Corporation (and its subsidiaries) (“Bausch + Lomb,” “we,” “us,” “our” or the “Company”) is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our mission is simple, yet powerful: helping you see better, to live better. Founded in 1853, Bausch + Lomb has a significant global research, development, manufacturing and commercial footprint of approximately 13,000 employees and a presence in approximately 100 countries.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 357.5 million (as of October 21, 2026) | 10-Q, October 28, 2026 |
|---|---|---|
| Public float | $557M (as of June 30, 2025) | 10-K, February 18, 2026 |
| Reportable segments | 3 (period ending September 30, 2026) | 10-Q, October 28, 2026 |
| Latest proxy statement | Meeting May 20, 2026 (filed April 10, 2026) | DEF 14A, April 10, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Florham Park, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| October 29, 2026 | Frederick Munsch SVP, Controller and CAO | Sale | 112,015 | $2.3M | Form 4, November 2, 2026 |
| August 10, 2026 | Frederick Munsch SVP, Controller and CAO | Sale | 52,900 | $888K | Form 4, August 12, 2026 |
| August 7, 2026 | Eschenbach Andrew C. Von Director | Sale | 18,559 | $307K | Form 4, August 10, 2026 |
| March 6, 2026 | A. Robert D. Bailey EVP & Chief Legal Officer | Buy | 14,600 | $250K | Form 4, March 10, 2026 |
| March 6, 2026 | Sam Eldessouky EVP and CFO | Buy | 4,000 | $69K | Form 4, March 10, 2026 |
| March 6, 2026 | Brent L. Saunders CEO and Chairman of the Board | Buy | 14,700 | $252K | Form 4, March 10, 2026 |
| March 3, 2026 | Thomas W. Ross Sr. Director | Buy | 4,500 | $80K | Form 4, March 4, 2026 |
| March 2, 2026 | Eduardo Alfonso Director | Buy | 4,300 | $77K | Form 4, March 3, 2026 |
Recent 8-K events
- 8-K filed 2026-10-28
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-28
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-10-13
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-06
- Item 1.01 Entry into a material definitive agreement
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 8.01 Other events
- 8-K filed 2026-07-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-20
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-18
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-02
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 8.01 Other events
- 8-K filed 2025-12-17
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Bausch & Lomb Corp
- What does Bausch & Lomb Corp do?
- Bausch & Lomb Corp is classified by the SEC as Ophthalmic Goods (SIC 3851). It is based in Vaughan, A6.
- What is Bausch & Lomb Corp's revenue?
- $5.1B for the fiscal year ending December 31, 2025, from its 10-K filed February 18, 2026.
- Is Bausch & Lomb Corp profitable?
- Bausch & Lomb Corp reported net income of -$360M for the fiscal year ending December 31, 2025.
- How many employees does Bausch & Lomb Corp have?
- About 13,000 as of December 31, 2025, as stated in its annual report.
- Who is the CFO of Bausch & Lomb Corp?
- Sam Eldessouky, EVP and CFO, as named in a 4 filed August 7, 2026.
- Where is Bausch & Lomb Corp headquartered?
- Vaughan, A6.
- What is Bausch & Lomb Corp's stock ticker?
- BLCO on NYSE.
- What industry is Bausch & Lomb Corp in?
- Ophthalmic Goods, SIC code 3851.
- What is Bausch & Lomb Corp's website?
- bausch.com.
- When does Bausch & Lomb Corp report earnings next?
- January 27, 2027. Source: estimate_8k_pattern.
- Is Bausch & Lomb Corp a public company?
- Yes. Bausch & Lomb Corp files with the SEC under CIK 0001860742 and trades as BLCO.
- Who audits Bausch & Lomb Corp?
- PricewaterhouseCoopers LLP, Florham Park, New Jersey, as named in its latest annual report (10-K).
- How many shares of Bausch & Lomb Corp are outstanding?
- 357.5 million shares as of October 21, 2026, from its 10-Q filed October 28, 2026.
- What is Bausch & Lomb Corp's public float?
- $557M as of June 30, 2025, as reported on the cover of its 10-K filed February 18, 2026.
- How many business segments does Bausch & Lomb Corp report?
- 3 reportable segments for the period ending September 30, 2026, from its 10-Q filed October 28, 2026.
- When is Bausch & Lomb Corp's annual shareholder meeting?
- May 20, 2026, per its proxy statement (DEF 14A) filed April 10, 2026.
- Have Bausch & Lomb Corp insiders traded stock recently?
- Since February 19, 2026, officers and directors reported 3 open-market sales worth about $3.5M and 9 purchases worth about $1.2M on Forms 4 and 5. The most recent: Frederick Munsch (SVP, Controller and CAO) sold 112,015 shares on October 29, 2026.